Business Context and Reporting Period
This Form 8-K, dated January 6, 2015, reports on events occurring on January 1, 2015, for Imprimis Pharmaceuticals, Inc. (the "Company"). The filing details the completion of an acquisition of South Coast Specialty Compounding, Inc. D/B/A Park Compounding ("Park"), a compounding pharmacy located in Irvine, California.
Key Financial Metrics and Transaction Details
The acquisition involved a mixed cash and stock consideration structure. The filing does not provide the Company's standalone revenue, profit, cash flow, or debt metrics for the period, as this is a current report focused on a specific transaction.
- Total Consideration: Approximately $4,137,500 (subject to working capital adjustments).
- Cash Paid at Closing: $3,000,000 (net of fees and expenses).
- Stock Issued at Closing: 63,525 shares valued at $500,000.
- Deferred Payments: 12 quarterly payments of $53,125 each, totaling $637,500 over three years.
- Contingent Equity: Sellers have the option to receive the final six payments (up to $318,750) in Company common stock instead of cash.
Material Changes
The primary material change is the expansion of the Company's operations through the acquisition of Park. Additionally, Dennis Saadeh, a seller, has entered into an employment agreement to serve as Senior Director of Corporate Development for Park. An affiliate of the sellers has also entered into a commercial lease agreement to lease premises to Park.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond standard legal disclaimers regarding the Purchase Agreement. The Company notes that financial statements and pro forma financial information regarding the acquisition will be filed as soon as practicable within the timeframe required by Form 8-K.
Investor Verification Checklist
- Verify the final working capital adjustment to the $3,000,000 cash purchase price.
- Confirm the issuance of the 63,525 shares of common stock and the subsequent impact on share count.
- Monitor future filings for the required financial statements and pro forma information for Park.
- Review the full text of the Stock Purchase Agreement (Exhibit 2.1) for representations, warranties, and indemnification terms.
- Track the execution of the deferred payment schedule and any election by sellers to convert the final six payments into equity.